- PharmAla Biotech (MDMA) began trading on the Canadian Securities Exchange (CSE) at market open on January 11, 2022
- PharmAla intends to support research into MDMA by being a trusted source of clinical-grade MDMA products
- PharmAla has also commenced preclinical research into two provisionally patented novel chemical entities to improve the molecules’ toxicology and safety
- PharmAla Biotech is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules
- PharmAla Biotech Holdings Inc. (CSE: MDMA) is down 13.64 per cent, trading at C$0.095 per share at 12:30 pm EST
PharmAla Biotech (MDMA) began trading its common shares on the Canadian Securities Exchange (CSE) at market open on January 11, 2022.
PharmAla intends to support research into MDMA by being a trusted source of clinical-grade MDMA products made under Good Manufacturing Practices (cGMP) for sale to all entities legally eligible to hold these substances. PharmAla has also commenced preclinical research into two provisionally patented novel chemical entities (NCEs) in the MDXX class, with the goal of improving the molecules’ toxicology and safety.
“At PharmAla, our goal is to both support clinical trials today by operating North America’s only clinical cGMP grade MDMA value chain, and to research and develop new patented drugs that will open the door for new treatments. Mental health is an area of growing importance that the COVID-19 pandemic has brought to the forefront. We intensely believe that these treatments can help address the very serious needs of patients facing certain mental health challenges,” said PharmAla COO Dr. Shane Morris.
PharmAla Biotech Inc. is a Canadian biotechnology company dedicated to the research, development, manufacture and sales of MDMA in service to the clinical research community.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is down 13.64 per cent, trading at C$0.095 per share at 12:30 pm EST.
